Marilyn F. Kraus, M.D is an Associate Professor of Psychiatry and Neurology. She is a senior research faculty in The Center for Cognitive Medicine. As a neuropsychiatrist, her area of expertise both clinically and in research for over ten years is the evaluation and neuropharmacologic treatment of neurobehavioral (cognitive, mood and behavior) disorders that result from brain injury. Her research focuses on neuropharmacologic interventions to improve function after traumatic brain injury (TBI), using functional brain imaging and oculomotor studies to assess outcomes. She has had multiple publications in this area, and lectures frequently. Most recently she was awarded a five-year K23 research grant from NIMH to study TBI. She also serves on the Professional Healthcare Board of the Midwest Brain Injury Clubhouse (a not-for-profit organization supporting brain injury survivors and families). Marilyn F. Kraus, M.D is an Associate Professor of Psychiatry and Neurology. She is a senior research faculty in The Center for Cognitive Medicine. As a neuropsychiatrist, her area of expertise both clinically and in research for over ten years is the evaluation and neuropharmacologic treatment of neurobehavioral (cognitive, mood and behavior) disorders that result from brain injury. Her research focuses on neuropharmacologic interventions to improve function after traumatic brain injury (TBI), using functional brain imaging and oculomotor studies to assess outcomes. She has had multiple publications in this area, and lectures frequently. Most recently she was awarded a five-year K23 research grant from NIMH to study TBI. She also serves on the Professional Healthcare Board of the Midwest Brain Injury Clubhouse (a not-for-profit organization supporting brain injury survivors and families).

Representative Publications

Kraus MF, Smith GS, Butters M, Donnell AJ, Dixon CE, Ma CY, Marion D. Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using Positron Emission Tomography (PET). Accepted for publication, Brain Injury, 0ctober 2004.

Kraus MF, Pavuluri M, Sweeney JA (2003). Functional MRI: Research and Clinical Applications in Neuropsychiatry. Contemporary Psychiatry 2(2):1-8

Kerr ME , Kamboh MI, Yookyung K, Kraus MF, Puccio AM, DeKosky ST, Marion DW (2003). Relationship between apoE4 allele and excitatory amino acid levels after traumatic brain injury. Crit Care Med 31 (9) :2371-2379

Kerr ME, Kraus M, Marion D, Kamboh I (1999) Evaluation of apolipoprotein E genotypes on cerebral blood flow and metabolism following traumatic brain injury. Adv Exp Med Biol 471: 117-24.

Dixon CE, Kraus MF, Ma X., Yan HQ, Griffith RG, Wolfson BM, Marion DW (1999) Amantadine improves water maze performance following traumatic brain injury in rats. Restorative Neurology and Neuroscience 14: 285-294.

Kerr M, Kraus MF (1998) Genetics and the central nervous system: apolipoprotein E and brain injury. AACN Clinical Issues: Advanced Practice in Acute and Critical Care 9(4): 524-530.

Kraus MF, Maki PM (1997). The effect of amantadine hydrochloride on neuropsychiatric sequelae of brain injury: Case studies and review. Journal of Neuropsychiatry and Clinical Neurosciences 9 (2): 222-230.